General topics
| No. | TOPIC |
|---|---|
| 1 | Haematopoietic stem cells |
| 2 | Stem cell mobilization, collection and engineering |
| 3 | CAR-based Cellular Therapy: preclinical |
| 4 | CAR-based Cellular Therapy: clinical |
| 5 | Cellular Therapy other than CARs |
| 6 | Gene Therapy |
| 7 | Experimental transplantation |
| 8 | New drug- and cell-based immune therapies |
| 9 | Non-haematopoietic stem cells |
| 10 | Regenerative medicine |
| 11 | Psychological issues |
| 12 | Pharmacology |
Transplant-specific topics
| no. | TOPIC |
|---|---|
| 13 | Stem cell source |
| 14 | Stem cell donor |
| 15 | Graft-versus-host disease – preclinical and animal models |
| 16 | Graft-versus-host disease – clinical |
| 17 | Infectious complications |
| 18 | Non-infectious early complications |
| 19 | Non-infectious late effects & quality of life / fertility |
| 20 | Conditioning regimens |
| 21 | Minimal residual disease, tolerance, chimerism and immune reconstitution |
| 22 | Paediatric issues |
| 23 | Experimental stem cell transplantation |
Disease-specific topics
| no. | TOPIC |
|---|---|
| 24 | Acute leukaemia |
| 25 | Aplastic anaemia |
| 26 | Autoimmune diseases |
| 27 | Chronic leukaemia and other myeloproliferative disorders |
| 28 | Granulocyte and osteoclast disorders |
| 29 | Haemoglobinopathy and inborn errors of metabolism |
| 30 | Immunodeficiency diseases and macrophages |
| 31 | Lymphoma |
| 32 | Multiple myeloma |
| 33 | Myelodysplastic syndromes |
| 34 | Solid tumours |
Data Management Group
| no. | TOPIC |
|---|---|
| 35 | Data Management |
Statistics
| no. | TOPIC |
|---|---|
| 36 | Statistics |
Quality Management Group
| no. | TOPIC |
|---|---|
| 37 | Accreditation |
| 38 | Quality management |
| 39 | Regulatory issues |
| 40 | Sharing best quality practices |
Care-specific topics
| no. | TOPIC |
|---|---|
| 41 | Care of the carer |
| 42 | Complementary therapies |
| 43 | Donor issues |
| 44 | Ethical issues |
| 45 | Impact of new therapies on patient care |
| 46 | Information and education |
| 47 | Management |
| 48 | Outpatient developments |
| 49 | Palliative care |
| 50 | Patient safety |
| 51 | Psycho-social issues |
| 52 | Protective care |
| 53 | Quality of life |
| 54 | Standards of care |
| 55 | Survivorship |
| 56 | Symptoms management |
| 57 | CAR-T or immune effector cells |